We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Antitrust in China's pharma sector – Bengbu action following big-bang reform

Adrian Emch

Adrian Emch,

Beijing

Andrew McGinty

Andrew McGinty,

Shanghai

Eugene Chen

Eugene Chen,

Shanghai

Jessie J. Xie

Jessie J. Xie,

Beijing

Roy G. Zou

Roy G. Zou,

Beijing

Jiaming Zhang

01 September 2015
On 26 August 2015, the National Development and Reform Commission (NDRC) made public its first antitrust enforcement decision in the pharmaceutical sector since launching the drug pricing reform earlier this year. Although the target of this enforcement action was a local government entity, pharmaceutical companies should expect continued antitrust intervention in parallel with the implementation of the pricing reform.
Adrian Emch

Adrian Emch,

Beijing

Andrew McGinty

Andrew McGinty,

Shanghai

Eugene Chen

Eugene Chen,

Shanghai

Jessie J. Xie

Jessie J. Xie,

Beijing

Roy G. Zou

Roy G. Zou,

Beijing

Jiaming Zhang

Loading data